Efficacy and safety of camrelizumab (a PD-1 inhibitor) combined with chemotherapy as a neoadjuvant regimen in patients with locally advanced non-small cell lung cancer.

Oncol Lett · 2022 · PMC9178701 · PMID 35720491

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an elevated trendno p-value reported

In addition, CPR also exhibited an elevated trend in the camrelizumab plus PC group compared with that of the PC group, but again the result was not statistically significant (25.8 vs. 8.3%; P=0.159) ( Fig. 1 ).

also in 278 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.